@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://purl.org/spar/pro/> .
@prefix ns2: <http://prismstandard.org/namespaces/basic/2.0/> .
@prefix ns3: <http://purl.org/vocab/frbr/core#> .
@prefix ns4: <http://purl.org/spar/datacite/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<> dcterms:license <https://creativecommons.org/publicdomain/zero/1.0/legalcode> .

<https://w3id.org/oc/meta/br/06201828990> a <http://purl.org/spar/fabio/Expression>,
        <http://purl.org/spar/fabio/JournalArticle> ;
    rdfs:label "br 06201828990" ;
    ns2:publicationDate "2019-08-02"^^xsd:date ;
    dcterms:title "A Phase 1/2, Open-Label Assessment Of The Safety, Tolerability, And Efficacy Of Transdermal Cannabidiol (ZYN002) For The Treatment Of Pediatric Fragile X Syndrome" ;
    ns4:hasIdentifier <https://w3id.org/oc/meta/id/06201854090>,
        <https://w3id.org/oc/meta/id/06550198836>,
        <https://w3id.org/oc/meta/id/06604706041> ;
    ns1:isDocumentContextFor <https://w3id.org/oc/meta/ar/06208165309>,
        <https://w3id.org/oc/meta/ar/06208165310>,
        <https://w3id.org/oc/meta/ar/06208165311>,
        <https://w3id.org/oc/meta/ar/06208165312>,
        <https://w3id.org/oc/meta/ar/06208165313>,
        <https://w3id.org/oc/meta/ar/06208165314>,
        <https://w3id.org/oc/meta/ar/06208165315>,
        <https://w3id.org/oc/meta/ar/06208165316>,
        <https://w3id.org/oc/meta/ar/06208165317> ;
    ns3:partOf <https://w3id.org/oc/meta/br/06201829953> .